Sandoz wades into Humira biosimilars

Share this article:

Novartis's generics arm, Sandoz, is taking on AbbVie's multi-indication medication Humira. The company announced Wednesday that it had kicked off a Phase III trial of an adalimumab biosimilar. It said the trial's goal is to “demonstrate efficacy, similarity and immunogenicity of the Sandoz product versus Humira” in moderate-to-severe plaque psoriasis patients.

The division's head of biopharmaceuticals and oncology injectables, Ameet Mallik, said in a statement that the Humira biosimilar will be “a key building block in our growing immunology portfolio” and that the company has Phase III trials in effect for biologics including Amgen's Enbrel and Roche's Rituxan.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.